TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases

Rachel A. Freedman, Rebecca S. Gelman, Carey K. Anders, Michelle E. Melisko, Heather A. Parsons, Anne M. Cropp, Kelly Silvestri, Christine M. Cotter, Kathryn P. Componeschi, Juan M. Marte, Roisin M. Connolly, Beverly Moy, Catherine H. Van Poznak, Kimberly L. Blackwell, Shannon L. Puhalla, Rachel C. Jankowitz, Karen L. Smith, Nuhad Ibrahim, Timothy J. Moynihan, Ciara C. O'SullivanJulie Nangia, Polly Niravath, Nadine Tung, Paula R. Pohlmann, Robyn Burns, Mothaffar F. Rimawi, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, Nancy U. Lin

Research output: Contribution to journal › Article › peer-review

244 Scopus citations

Fingerprint

Dive into the research topics of 'TBCRC 022: A phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences